share_log

Morgan Stanley Upgrades Esperion Therapeutics to Equal-Weight, Announces $9 Price Target

Benzinga Real-time News ·  Feb 3, 2023 06:23

Morgan Stanley analyst Jeffrey Hung upgrades Esperion Therapeutics (NASDAQ:ESPR) from Underweight to Equal-Weight and announces $9 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment